USPTO serial 79055263
HIPERFECT
Reviewed by CopyMark Law Group
Reg. 3754819Status 706Registered
- Filing date
- Status date
- Registration date
- Mar 2, 2010
- Examiner
- PHAM, LANA H
- Law office
- GENERIC WEB UPDATE
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with HIPERFECT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Victoria Friedman
Victoria Friedman Dennemeyer & Associates, LLC2 North Riverside Plaza, Suite 1500Chicago, IL 60606UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical, biochemical and biotechnological products for industrial and scientific purposes, namely, [ nucleic acids for laboratory and laboratory research use, enzymes, polymerases, chemical and biochemical reagents for staining and marking for laboratory and research use, chemical and biochemical reagents commonly known as probes for detecting and analyzing molecules in protein or nucleic acid arrays, ] transfection reagents for research purposes, anionic, cationic and zwitterionic lipids and mixtures thereof for introducing chemical, biochemical and biotechnological products into cells, [ chemical buffers used in analytical chemistry and biochemistry, aqueous and non-aqueous solutions of alcohols and/or salts, namely, solutions containing isopropanol, ethanol, methanol, propanol, butanol or PEG and solutions containing chaotropic salts, distilled water, column and membrane material comprising silicium dioxide for the isolation, purification or separation of chemical, biochemical and biotechnological products, none of the foregoing for medical or veterinary purposes; ] chemicals and biochemicals for industrial and scientific purposes, [ namely, reagents for research purposes for industrial and commercial use for sample preparation, purification, lysis, modification and manipulation of cells and tissues, ] namely, transfection chemical reagents for non-medical purposes, chemical reagents for non-medical purposes [ and aromatic solvents for industrial and commercial use for performing marking, separating, isolating, purification, amplification, and/or analysis methods of biopolymers, namely, nucleic acids, enzymes, proteins, macromolecules and biologically active substances for separation, modification, analysis, marking, amplification and purification of biological and chemical compounds, none of the foregoing for medical or veterinary purposes; kits comprising chemical preparations for scientific and chemicals for industrial purposes, ] kits comprising biochemicals for scientific or industrial purposes and kits comprising biotechnological products for scientific purposes, namely, biochemical catalysts, transfection chemical reagents for non-medical purposes, anionic, cationic and zwitterionic lipids and mixtures thereof for introducing chemical, biochemical and biotechnological products into cells, nucleic acids for laboratory use, oligonucleotides for scientific research, enzymes for scientific and research purposes, proteins for scientific research, chemical and biochemical reagents for staining and marking for non-medical purposes, chemical and biochemical reagents commonly known as probes for detecting and analysing molecules in protein or nucleic acid arrays and/or comprising chemical buffers for industrial and commercial use for sample preparation, purification, lysis, modification and manipulation of cells or tissue and for performing marking, separating, isolating, purification, amplification and/or analysis methods for biopolymers, namely, nucleic acids, enzymes, proteins, macromolecules, none of the foregoing for medical or veterinary purposes | ACTIVE | — |
| 005 | [ Diagnostic preparations for medical and veterinary purposes; pharmaceutical and veterinary products, namely, nucleic acid sequences, chemical reagents and biochemical preparations for medical or veterinary purposes; nucleic acid sequences for diagnostic and/or pharmaceutical purposes; anionic, cationic and zwitterionic lipids and mixtures thereof for the introduction of molecules into cells for diagnostic and/or pharmaceutical purposes; medical or diagnostic transfection reagents for diagnostic and/or pharmaceutical purposes; kits comprising chemical reagents for medical and veterinary-diagnostic purposes, kits comprising biochemical preparations for medical and veterinary-diagnostic purposes and kits comprising biotechnological products, namely, transfection reagents, anionic, cationic and zwitterionic lipids and mixtures thereof for the introduction of molecules into cells, all of the foregoing for medical, veterinary and/or diagnostic purposes ] | SECTION 71 - CANCELLED | — |
| 009 | [ Scientific apparatuses, instruments and equipment and laboratory instruments and measuring apparatuses and instruments in particular for research, medical, diagnostic and analysis purposes, namely, disposable laboratory articles, namely, plastic vessels, sample storage vessels, reaction and collection vessels and plates, multi-well plates, tips, including filter tips and dispenser tips, pipette tips and tip boxes, tubes, microtubes and tubes for PCR and micro centrifuges and micro-injection, capillaries, curvettes, spin columns, cartridges and columns filed with chromatographic material for the separation, purification, and isolation of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material, in particular nucleic acids from biological or biochemical sample material, in particular for transfection, racks and holders for samples storage vessels, tubes, syringes and tips; sample presentation devices, mircroarrays, chips, MALDI-MS presentation devices; laboratory robots, robotic workstations and systems and laboratory incubators for diagnostic, clinical and research applications for the preparation, modification, isolation, crystallization, handling, amplification and manipulation of samples and for the transfecting, marking, separation, isolation, purification, reproduction and analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material, in particular nucleic acids from biological or biochemical sample material, laboratory apparatuses and equipment for dosage, dispensing, transferring, temperature equalizing, agitating, mixing, diluting, concentrating, transfecting and separating of liquids, MALDI- apparatuses, workstations for reading and handling multi-well plates for the analysis of biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material in particular nucleic acids from biological or biochemical sample material, in particular for nucleic acid amplification, in particular by polymerase chain reaction (PCR); laboratory equipment, namely, cyclers, thermocyclers, lysis apparatuses, disrupters, physico-chemical, bio-chemical, optical and electronic analysis apparatus and equipment, in particular photometers, spectrophotometers, optical scanners for detection of fluorescence and colorimetric signals; apparatuses for processing cells or liquids containing cells in particular electroporators, electrofusion apparatuses, transfection apparatuses, micro injectors and micro manipulators; vacuum chambers for chromatography, purification, separation and characterization of natural and synthetic biopolymers, nucleic acids, oligonucleotides, proteins, macromolecules and biologically active substances from sample material; centrifuges; vacuum systems for laboratory use, vacuum concentrators; centrifugal concentrators; rotors for laboratory centrifuges and vacuum concentrators, mixers; mechanical, electronical and automatical pipettes and dispensers for dispensing liquid for laboratory research and analysis purposes ] | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by QIAGEN GmbH
- Other trademarks owned by QIAGEN GmbH
- Other trademarks owned by QIAGEN GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Similar marks named HIPERFECT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 20, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jan 3, 2021 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Nov 24, 2020 | INPS | PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Nov 24, 2020 | INPC | INVALIDATION PROCESSED | — |
| Nov 12, 2020 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Mar 12, 2020 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Mar 12, 2020 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Mar 12, 2020 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 29, 2020 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Mar 2, 2019 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jan 25, 2018 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Jun 2, 2017 | INNP | PARTIAL INVALIDATION PROCESSED BY THE IB | — |
| Feb 18, 2017 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Feb 18, 2017 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Nov 3, 2016 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Mar 3, 2016 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Mar 3, 2016 | C75P | REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Mar 2, 2016 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 2, 2016 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Dec 14, 2013 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 5, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 28, 2012 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jul 28, 2012 | PLGL | ASSIGNED TO PARALEGAL | — |
| Mar 17, 2011 | PC.D | PETITION TO DIRECTOR DISMISSED | — |
| Feb 18, 2011 | APET | ASSIGNED TO PETITION STAFF | — |
| Jan 12, 2011 | TPDR | TEAS PETITION TO DIRECTOR RECEIVED | — |
| Dec 16, 2010 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 17, 2010 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 17, 2010 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 2, 2010 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 2, 2010 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 15, 2009 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 15, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 10, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 7, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 27, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 27, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 22, 2009 | ALIE | ASSIGNED TO LIE | — |
| Oct 13, 2009 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Oct 13, 2009 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Oct 13, 2009 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Oct 13, 2009 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Jun 29, 2009 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Jun 19, 2009 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jun 11, 2009 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Apr 13, 2009 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| Apr 13, 2009 | GNSF | SUBSEQUENT FINAL EMAILED | — |
| Apr 13, 2009 | CFRC | SUBSEQUENT FINAL REFUSAL WRITTEN | — |
| Mar 9, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 9, 2009 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Mar 9, 2009 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 9, 2009 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 9, 2009 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 9, 2009 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Feb 6, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 6, 2009 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 6, 2009 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 6, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 22, 2009 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Aug 22, 2008 | RFNP | REFUSAL PROCESSED BY IB | — |
| Aug 7, 2008 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 7, 2008 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 7, 2008 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 6, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 25, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 25, 2008 | NWAP | NEW APPLICATION ENTERED | — |
| Jul 24, 2008 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |